breast-cancer

Two HER2 breast cancer mutations have opposite effects on drug binding—one reduces, one enhances it.

Molecular dynamics simulations of HER2 D769H and D769Y mutations showed contrasting effects. D769H destabilized the drug complex (equilibrium at 100 ps vs. 150 ps for wild-type, suggesting reduced drug retention). D769Y enhanced ligand binding beyond wild-type strength. Both mutations increased…

Dan Manning

Dan Manning

— 1 min read
Share
Two HER2 breast cancer mutations have opposite effects on drug binding—one reduces, one enhances it.

Two HER2 breast cancer mutations have opposite effects on drug binding—one reduces, one enhances it.

Molecular dynamics simulations of HER2 D769H and D769Y mutations showed contrasting effects. D769H destabilized the drug complex (equilibrium at 100 ps vs. 150 ps for wild-type, suggesting reduced drug retention). D769Y enhanced ligand binding beyond wild-type strength. Both mutations increased structural flexibility near the mutation site.

Key Findings

  • D769H mutation reduces drug retention (equilibrium 100 ps vs. 150 ps for wild-type)
  • D769Y mutation enhances drug binding beyond wild-type
  • Both mutations increase structural flexibility near mutation site
  • RMSD analysis shows increased conformational instability in mutants
  • Mutation-specific therapeutic strategies are needed

Implications

D769H patients may need alternative HER2-targeted drugs; D769Y carriers may respond better to standard agents. Computational screening could guide personalized treatment.

Caveats

Computational study only; abstract-only. In silico predictions require experimental and clinical validation. Results for two specific mutations may not generalize.

Source: Journal of biological physics — 2026-04-11

Read more